{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:35:52Z","timestamp":1791999352021,"version":"4.4.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014605","name":"Sage Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jad.2023.01.077","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T04:54:45Z","timestamp":1674622485000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation"],"prefix":"10.1016","volume":"326","author":[{"given":"Nadav Liam","family":"Modlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namik","family":"Kirlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Lennard-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Schlosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-7358(02)00146-0","article-title":"A review of therapist characteristics and techniques positively impacting the therapeutic alliance","volume":"23","author":"Ackerman","year":"2003","journal-title":"Clin. Psychol. Rev."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","article-title":"Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects","volume":"4","author":"Aday","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.jad.2023.01.077_bb0015","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.01.077_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2011.00270","article-title":"Therapeutic Alliance and outcome of psychotherapy: historical excursus, measurements, and prospects for research","volume":"2","author":"Ardito","year":"2011","journal-title":"Front. Psychol."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/sim.4780010412","article-title":"The role of randomization in clinical trials","volume":"1","author":"Armitage","year":"1982","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/wps.20147","article-title":"Harnessing the potential of the therapeutic alliance","volume":"13","author":"Arnow","year":"2014","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2023.01.077_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/070674370805300605","article-title":"Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy","volume":"53","author":"Bagby","year":"2008","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.077_bb0040","series-title":"Anxiety and Its Disorders, Second Edition: The Nature and Treatment of Anxiety and Panic","author":"Barlow","year":"2004"},{"key":"10.1016\/j.jad.2023.01.077_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2017_474","article-title":"Classic hallucinogens and mystical experiences: phenomenology and neural correlates","volume":"393\u2013430","author":"Barrett","year":"2017","journal-title":"Behav. Neurobiol. Psychedelic Drugs"},{"issue":"11","key":"10.1016\/j.jad.2023.01.077_bb0060","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.077_bb3000","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","article-title":"Neuroticism is associated with challenging experiences with psilocybin mushrooms","volume":"117","author":"Barrett","year":"2017","journal-title":"Person. Ind. Diff."},{"key":"10.1016\/j.jad.2023.01.077_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2021.685530","article-title":"Are you able to trust Me? Analysis of the relationships between personality traits and the assessment of attractiveness and trust","volume":"15","author":"Bartosik","year":"2021","journal-title":"Front. Hum. Neurosci."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0022167817706884","article-title":"Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis","volume":"57","author":"Belser","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1037\/h0085885","article-title":"The generalizability of the psychoanalytic concept of the working alliance","volume":"16","author":"Bordin","year":"1979","journal-title":"Psychotherapy"},{"issue":"9","key":"10.1016\/j.jad.2023.01.077_bb0085","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","article-title":"Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies","volume":"34","author":"Breeksema","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2023.01.077_bb0090","article-title":"Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a transdiagnostic","volume":"13","author":"Brennan","year":"2022","journal-title":"Trans- Drug Model. Front. Psychol."},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1037\/a0016608","article-title":"A proposal for a dimensional classification system based on the shared features of the DSM-IV anxiety and mood disorders: implications for assessment and treatment","volume":"21","author":"Brown","year":"2009","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.jad.2023.01.077_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cpr.2019.04.002","article-title":"A meta-analytic review of personality traits and their associations with mental health treatment outcomes","volume":"70","author":"Bucher","year":"2019","journal-title":"Clin. Psychol. Rev."},{"issue":"10","key":"10.1016\/j.jad.2023.01.077_bb0105","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: if so, so what?","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacology"},{"issue":"15","key":"10.1016\/j.jad.2023.01.077_bb0110","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jad.2023.01.077_bb0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"issue":"11","key":"10.1016\/j.jad.2023.01.077_bb0125","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.jad.2023.01.077_bb0135","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/jclp.20400","article-title":"Experiential avoidance as a functional dimensional approach to psychopathology: an empirical review","volume":"63","author":"Chawla","year":"2007","journal-title":"J. Clin. Psychol."},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1037\/0021-843X.100.3.316","article-title":"Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications","volume":"100","author":"Clark","year":"1991","journal-title":"J. Abnorm. Psychol."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1037\/pst0000169","article-title":"A meta-analysis of the association between patients\u2019 early treatment outcome expectation and their posttreatment outcomes","volume":"55","author":"Constantino","year":"2018","journal-title":"Psychotherapy"},{"issue":"6","key":"10.1016\/j.jad.2023.01.077_bb0155","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0191-8869(92)90236-I","article-title":"Four ways five factors are basic","volume":"13","author":"Costa","year":"1992","journal-title":"Personal. Individ. Differ."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0160","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"210","key":"10.1016\/j.jad.2023.01.077_bb0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","article-title":"Understanding and misunderstanding randomized controlled trials","volume":"1982","author":"Deaton","year":"2018","journal-title":"Soc. Sci. Med."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0170","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder","volume":"11","author":"Doss","year":"2021","journal-title":"TranslationalPsychiatry"},{"key":"10.1016\/j.jad.2023.01.077_bb0175","series-title":"The Role of Outcome Expectancy in Therapeutic Change Across Psychotherapy Versus Pharmacotherapy for Depression","volume":"7","author":"Dozois","year":"2019"},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/wps.20910","article-title":"Thinking too much: rumination and psychopathology","volume":"20","author":"Ehring","year":"2021","journal-title":"World Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2023.01.077_bb0185","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.paid.2008.01.013","article-title":"Characteristics of emotion regulation in recovered depressed versus never depressed individuals","volume":"44","author":"Ehring","year":"2008","journal-title":"Personal. Individ. Differ."},{"issue":"6","key":"10.1016\/j.jad.2023.01.077_bb0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/(SICI)1520-6807(199911)36:6<451::AID-PITS1>3.0.CO;2-E","article-title":"Extending big-five theory into childhood: a preliminary investigation into the relationship between big-five personality traits and behavior problems in children","volume":"36","author":"Ehrler","year":"1999","journal-title":"Psychol. Sch."},{"key":"10.1016\/j.jad.2023.01.077_bb0195","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fpsyt.2019.00456","article-title":"Placebo effects in psychotherapy: a framework","volume":"10","author":"Enck","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2023.01.077_bb0200","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1037\/cou0000336","article-title":"Investigating the impact of early alliance on predicting subjective change at posttreatment: an evidence-based souvenir of overlooked clinical perspectives","volume":"66","author":"Fl\u00fcckiger","year":"2019","journal-title":"J. Couns. Psychol."},{"issue":"27","key":"10.1016\/j.jad.2023.01.077_bb0205","doi-asserted-by":"crossref","first-page":"9673","DOI":"10.1073\/pnas.0504136102","article-title":"The human brain is intrinsically organized into dynamic, anticorrelated functional networks","volume":"102","author":"Fox","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.077_bb0215","series-title":"Presented at the American Psychiatric Association Annual Meeting, May 2022, New Orleans, LA","article-title":"The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: Results from a phase IIb randomized controlled trial","author":"Goodwin","year":"2022"},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0220","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose- related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.077_bb0230","article-title":"Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy","author":"Gukasyan","year":"2021","journal-title":"Transcult. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0235","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/21642850.2014.912945","article-title":"Autonomous and controlled motivational regulations for multiple health-related behaviors: between- and within-participants analyses","volume":"2","author":"Hagger","year":"2014","journal-title":"Health Psychol. Behav. Med."},{"key":"10.1016\/j.jad.2023.01.077_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.jad.2023.01.077_bb0245","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra- pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0250","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF03395492","article-title":"Measuring experiential avoidance: a preliminary test of a working model","volume":"54","author":"Hayes","year":"2004","journal-title":"Psychol. Rec."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0255","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/0269881121992676","article-title":"Dose-response relationships of psilocybin-induced subjective experiences in humans","volume":"35","author":"Hirschfeld","year":"2021","journal-title":"J. Psychopharmacol. (Oxford, Engl.)"},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0260","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy","volume":"74","author":"Horton","year":"2021","journal-title":"Am. J. Psychother."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1037\/0022-0167.38.2.139","article-title":"Relation between working alliance and outcome in psychotherapy: a meta-analysis","volume":"38","author":"Horvath","year":"1991","journal-title":"J. Couns. Psychol."},{"issue":"11","key":"10.1016\/j.jad.2023.01.077_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140771","article-title":"Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed individuals using the personalized advantage index approach","volume":"10","author":"Huibers","year":"2015","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0275","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7334\/psicothema2015.211","article-title":"Motivation for change as a predictor of treatment response for dysthymia","volume":"28","author":"Ibanez","year":"2016","journal-title":"Psicothema"},{"issue":"6","key":"10.1016\/j.jad.2023.01.077_bb0280","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.077_bb0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cpr.2005.09.001","article-title":"Meta-analysis of therapeutic relationship variables in youth and family therapy: the evidence for different relationship variables in the child and adolescent treatment outcome literature","volume":"26","author":"Karver","year":"2006","journal-title":"Clin. Psychol. Rev."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0300","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0145445500242006","article-title":"The impact of interpersonal patient and therapist behavior on outcome in cognitive-behavior therapy","volume":"24","author":"Keijsers","year":"2000","journal-title":"Behav. Modif."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0305","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10503307.2015.1114687","article-title":"Convergence in patient\u2013therapist therapeutic alliance ratings and its relation to outcome in chronic depression treatment","volume":"27","author":"Laws","year":"2016","journal-title":"Psychother. Res."},{"issue":"11","key":"10.1016\/j.jad.2023.01.077_bb0310","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jad.2023.01.077_bb0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","article-title":"A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding","volume":"33","author":"Madsen","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0320","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1037\/0022-006X.68.3.438","article-title":"Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review","volume":"68","author":"Martin","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.jad.2023.01.077_bb0325","series-title":"The Art and Science of Personality Development","author":"McAdams","year":"2015"},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0330","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1348\/014466509X479186","article-title":"Autonomous and controlled motivation and interpersonal therapy for depression: moderating role of recurrent depression","volume":"49","author":"McBride","year":"2010","journal-title":"Br. J. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2023.01.077_bb202301240638316746","series-title":"The SAGE Handbook of Personality Theory and Assessment Volume 1 \u2014 Personality Theories and Models","first-page":"273","article-title":"Empirical and theoretical status of the five-factor model of personality traits","author":"McCrae","year":"2008"},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0340","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1037\/a0031994","article-title":"Rumination as a mechanism linking stressful life events to symptoms of depression and anxiety: longitudinal evidence in early adolescents and adults","volume":"122","author":"Michl","year":"2013","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.jad.2023.01.077_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic Alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2016","journal-title":"Clin. Pharmacol. Therapeutics"},{"issue":"5","key":"10.1016\/j.jad.2023.01.077_bb0360","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1745-6924.2008.00088.x","article-title":"Rethinking rumination","volume":"3","author":"Nolen-Hoeksema","year":"2008","journal-title":"Perspect. Psychol. Sci."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0365","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1037\/a0022161","article-title":"Evidence-based therapy relationships: research conclusions and clinical practices","volume":"48","author":"Norcross","year":"2011","journal-title":"Psychotherapy"},{"key":"10.1016\/j.jad.2023.01.077_bb0370","article-title":"A meta-analysis of self-determination theory-informed intervention studies in the health domain: effects on motivation, health behavior, physical, and psychological health","volume":"1\u201331","author":"Ntoumanis","year":"2020","journal-title":"Health Psychol. Rev."},{"key":"10.1016\/j.jad.2023.01.077_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.965641","article-title":"Therapeutic setting as an essential component of psychedelic research methodology: reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder","volume":"13","author":"Okano","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neubiorev.2012.09.004","article-title":"The biological and psychological basis of neuroticism: current status and future directions","volume":"37","author":"Ormel","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118143","article-title":"The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network","volume":"10","author":"Palhano-Fontes","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jad.2023.01.077_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.625380","article-title":"What research evidence is valid for psychotherapy research?","volume":"11","author":"Philips","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.077_bb0400","doi-asserted-by":"crossref","DOI":"10.1108\/MHRJ-12-2021-0091","article-title":"The active factor of alliance in psychotherapy: differentiation of therapeutic alliance quality according to the psychotherapist\u2019s theoretical orientation and type of disorder","author":"Prusi\u0144ski","year":"2022","journal-title":"Ment. Health Rev. J."},{"issue":"9","key":"10.1016\/j.jad.2023.01.077_bb0405","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.077_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.jad.2023.01.077_bb0415","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2023.01.077_bb0420","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","article-title":"Psychedelics in the treatment of unipolar mood disorders: a systematic review","volume":"30","author":"Rucker","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0425","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/02698811211064720","article-title":"The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo- controlled trial involving simultaneous psilocybin administration and preparation","volume":"36","author":"Rucker","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.jad.2023.01.077_bb0430","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00213-019-05279-z","article-title":"Replication and extension of a model predicting response to psilocybin","volume":"236","author":"Russ","year":"2019","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0435","first-page":"1","article-title":"States and traits related to the quality and consequences of psychedelic experiences","volume":"6","author":"Russ","year":"2019","journal-title":"Psychol. Conscious. Theory Res. Pract."},{"key":"10.1016\/j.jad.2023.01.077_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.jad.2023.01.077_bb0445","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1037\/0022-006X.71.3.452","article-title":"Prediction of treatment outcome from relationship variables in child and adolescent therapy: a meta-analytic review","volume":"71","author":"Shirk","year":"2003","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.jad.2023.01.077_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50612-3","article-title":"Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat","volume":"9","author":"Smigielski","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2023.01.077_bb0455","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2019.04.009","article-title":"Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects","volume":"196","author":"Smigielski","year":"2019","journal-title":"NeuroImage"},{"key":"10.1016\/j.jad.2023.01.077_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.774736","article-title":"The need for psychedelic-assisted therapy in the black community and the burdens of its provision","volume":"12","author":"Smith","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.01.077_bb0465","first-page":"1341","article-title":"Randomized controlled trials - a matter of design","volume":"12","author":"Spieth","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jad.2023.01.077_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.586682","article-title":"Development and evaluation of a therapist training program for psilocybin therapy for treatment- resistant depression in clinical research","volume":"12","author":"Tai","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2023.01.077_bb0480","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.jad.2023.01.077_bb0485","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881117711712","article-title":"Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy","volume":"31","author":"Wagner","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.01.077_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.brat.2020.103573","article-title":"Reflecting on rumination: consequences, causes, mechanisms and treatment of rumination","volume":"127","author":"Watkins","year":"2020","journal-title":"Behav. Res. Ther."},{"issue":"5","key":"10.1016\/j.jad.2023.01.077_bb0495","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients' accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0500","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.jad.2023.01.077_bb0505","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10503300600919380","article-title":"Autonomous motivation for therapy: a new common factor in brief treatments for depression","volume":"17","author":"Zuroff","year":"2007","journal-title":"Psychother. Res."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:38:18Z","timestamp":1759030698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":94,"alternative-id":["S0165032723000964"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.01.077","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.01.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}